Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of
America (USA).
The trial is planned to investigate the safety and efficacy of NovoSeven® in the management
of post-operative bleeding in patients following cardiac surgery.